BYNFEZIA

Generic name: octreotide

Used for: Acromegaly (too much growth hormone) · Diarrhea and flushing from carcinoid tumors · Watery diarrhea from VIP-secreting tumors (VIPomas) · 2 more

How do you pay?

How to pay the least

Ask for the cash price

BYNFEZIA

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you.

  1. Ask your pharmacy for BYNFEZIA’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameBYNFEZIA
Authorized genericoctreotide
Regular genericoctreotide
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Other forms onlyAsk your doctor
Same as BYNFEZIA?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from BYNFEZIA’s maker. Ask the pharmacy for BYNFEZIA’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is BYNFEZIA itself, from the same company, sold without the brand name, and usually for less. For now BYNFEZIA is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Sold only in a different form, strength or formula. Switching to one would need a new prescription, so ask your prescriber whether it could work for you. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for BYNFEZIA’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

BYNFEZIA PEN is a s o matostatin analogue indicated:

  • Acromegaly: To reduce blood levels of growth hormone (GH) and insulin growth factor 1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses.
  • Carcinoid Tumors: For the symptomatic treatment of patients with m eta static c a rcinoid t u mo rs where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease.
  • Vasoactive Intestinal Peptide Tumors (VIPomas): For the treatment of profuse watery diarrhea associated with VIP-secreting tumors.

Limitations of Use

Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with octreotide injection; these trials were not optimally designed to detect such effects.

Source: the FDA label for BYNFEZIA (Sun Pharmaceutical Industries, Inc.), February 21, 2025. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/bynfezia/